COMP <GO>
PDEX vs LLY // EV/EBITDA & P/E VALUATION
Pro-Dex Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PDEX 2
— LLY 11
▲ EV/EBITDA & P/E VALUATION LEADER: PDEX
LAST: $61.60 (-2.52%) • MKT CAP: $199.2M
valuation
16.5x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PDEX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PDEX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 29.30% | 83.64% | -54.34 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 23.20% | 32.36% | -9.16 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 16.5x | 36.4x | -19.92 | PDEX | /valuation <GO> |
| Free Cash Flow Yield | -1.47% | 2.30% | -3.77 | LLY | /fcf-yield <GO> |
| Operating Margin | 16.10% | 40.21% | -24.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 13.50% | 31.90% | -18.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 23.70% | 45.51% | -21.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.08 | 9.29 | -0.21 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.5 | 66.6 | -28.05 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.6x | 26.3x | -7.65 | PDEX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $199.2M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PDEX REV | LLY REV | PDEX GROSS % | LLY GROSS % | PDEX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $66.6M | $65.18B | 29.3% | 83.0% | -$2.9M | $16.81B |
| FY 2024 | $53.8M | $45.04B | 27.0% | 81.3% | $6.2M | $8.82B |
| FY 2023 | $46.1M | $34.12B | — | 79.3% | $5.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PDEX // BETA —
LLY // BETA 0.51